Carboplatin alone or in combination in high-risk acute nonlymphoblastic leukemia.

@article{Sanz1992CarboplatinAO,
  title={Carboplatin alone or in combination in high-risk acute nonlymphoblastic leukemia.},
  author={Miguel A Sanz and Guillermo Sanz and Jes{\'u}s Antornio Alvarez Mart{\'i}nez and Leonor Senent and Francisco Zamora L{\'o}pez and Javier Jolonch Palau and Guillermo Colmenarejo Mart{\'i}n and Isidro Jarque},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={1992},
  volume={3 Suppl 3},
  pages={
          39-42
        }
}
The use of newly developed antileukemic agents is one of the therapeutic options available to overcome clinical resistance in refractory or other high-risk acute leukemias. Carboplatin is a second-generation platinum compound that has demonstrated significant activity against acute leukemia, particularly when administered via continuous intravenous infusion in phase I clinical trials. Based on the preliminary reports of these trials, we designed a phase II clinical trial to evaluate the… CONTINUE READING
BETA